Abstract:Background Drug-eluting stents (DES) have been shown to significantly reduce clinical events and angiographic restenosis in the treatment of coronary artery disease (CAD). This study was conducted to assess the long-term efficacy and safety of the polymer-based sirolimus-eluting cobalt-chromium Firebird 2 (TM) stents in the treatment of patients with CAD.Methods This first-in-man study using the Firebird 2 (TM) stent is a prospective, historically-controlled multicenter clinical study, which enrolled 67 patients with CAD who were treated with the sirolimus-eluting cobalt-chromium stent (Firebird 2 (TM), Microport Shanghai, Firebird 2 group), compared to another 49 patients treated with a bare cobalt alloy stent (Driver, Medtronic, control group). Continued 2-year clinical follow-up was performed after getting the initial 6-month angiographic and 1-year clinical follow-up. The incidence of major adverse cardiac events (MACE) including cardiac death, reinfarction and target lesion revascularization (TLR) and stent thrombosis were compared between the two groups.Results All patients in the Firebird 2 group (100.0%) and 48 patients in the control group (98.0%) completed the 2-year clinical follow-up. At the 1-year follow-up the use of the Firebird 2 stent was highly effective, resulting in a significant 94% decrease of TLR (26.5% in the control group and 1.5% in the Firebird 2 group, P<0.0001). A significant difference in TLR was maintained at 2-year follow-up, Firebird 2 group 1.5% and the control group 31.3% (P<0.0001). Between 1- and 2-year post-stenting, no more TLR occurred in the Firebird 2 group compared with two cases in the control group (P>0.05). There was a 1.5% incidence of MACE at 1- and 2-year follow-up in the Firebird 2 group, compared with 26.5% and 33.3% in the control group, respectively (all P<0.0001). The cumulative 1- and 2-year MACE free survival rates were 98.5% in the Firebird 2 group vs 73.5% and 66.7% in the control group (log rank P<0.0001). No case of stent thrombosis occurred during 2-year follow-up in the Firebird 2 group, compared with one case that suffered a definite stent thrombosis in the control group at 19-month post-stenting: this patient presented with unstable angina pectoris and was treated by balloon angioplasty.Conclusions Compared with the bare cobalt alloy stent, the Firebird 2 (TM) sirolimus-eluting cobalt-chromium stent is safe and effective in treating patients with CAD. The use of this stent was associated with a sustained clinical benefit and significantly lower rate of TLR and MACE up to 2 years post-stenting.

Clinical Contrast Investigation of Firebird and Cypher Rapamycin Eluting Stent

Study of long-term safety and efficacy of domestic Firebird rapamycin-eluting stent

A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial

Biolimus-coated Versus Paclitaxel-Coated Balloons for Coronary In-Stent Restenosis (BIO ASCEND ISR): a Randomised, Non-Inferiority Trial.

Firebird Sirolimus Eluting Stent Versus Bare Mental Stent in Patients with ST-segment Elevation Myocardial Infarction

Long-Term Effects of Drug-Eluting Stents Versus Bare Metal Stents on Patients with Acute St-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Outcomes of 3-Year Clinical Follow-Up

Sirolimus-eluting Cobalt Alloyed Stents in Treating Patients with Coronary Artery Disease: Six-Month Angiographic and One-Year Clinical Follow-Up Result A Prospective, Historically Controlled, Multi-Center Clinical Study

Efficacy and Safety of Firebird Sirolimus-Eluting Stent in Treatment of Complex Coronary Lesions in Chinese Patients: One-Year Clinical and Eight-Month Angiographic Outcomes from the FIREMAN Registry.

Mid-term result of implantation of drug eluted stent for diabetic patients with multivessel coronary artery lesions

Effectiveness of drug eluting stents in patients with small coronary artery lesions

[Comparison of Rapamycin and Paclitaxel Eluting Stent in Patients with Multi-Vessel Coronary Disease].

Sirolimus-eluting Cobalt-Chromium Stents: Two-Year Clinical Results from First-in-man Study on the Firebird 2TM Stent

Two-year results and subgroup analyses of the PEPCAD China in-stent restenosis trial: A prospective, multicenter, randomized trial for the treatment of drug-eluting stent in-stent restenosis.

Comparison of Drug-Eluting Stents with Bare Metal Stents Implantation for the Treatment of Acute ST-elevation Myocardial Infarction: 2-Year Clinical Outcomes from Single-Center Registry.

A study of treatment with different drug eluting stents in coronary heart disease

Six-month Clinical Outcomes of Firebird 2TM Sirolimus-Eluting Stent Implantation in Real-World Patients with Coronary Artery Diseases

AS-023: Efficacy and Safety of a Novel Non-Symmetrical, Biodegradable Polymer-Coated Sirolimus-Eluting Stent in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Effect of Drug Eluting stent Implantation in the Treatment of Coronary Artery In-stent Restenosis in a Longterm Clinical Follow-up

[Comparison of the Effects of Rapamycin-Eluting Stent Implantation and Coronary Artery Bypass Grafting in Treatment of Patients with Multi-Vessel Coronary Disease].

Short and Intermediate Term Clinical Outcome of Sirolimus-Eluting Stent Implantation in Patients with ST-segment Elevation Myocardial Infarction

A cell membrane like biomimetic drug-eluting coronary stent